Navigation Links
Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature

MOUNTAIN VIEW, Calif. May 26, 2010 Complete Genomics Inc., a third-generation human genome sequencing company, today announced that Genentech Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), used the company's sequencing, bioinformatics and analytics services to sequence and compare a patient's primary lung tumor and adjacent normal tissue. Tumor-normal pairs like this allow researchers to compare the patient's genome before and after it was altered by the cancer; the patient's normal genome serves as the ideal control. This is the first time that such a comparison has been made across the whole genome for a lung cancer patient. Genentech's findings will be published online in Nature later today in a paper titled "The mutation spectrum revealed by paired genome sequences from a lung cancer patient."

Complete Genomics sequenced the patient's cancer and normal genome to a depth of 60x and 46x, respectively, providing high-resolution results and allowing somatic variations to be called with high confidence. This depth of sequencing enabled the Genentech researchers to identify a large number of somatic mutations and structural variations in the non-small cell lung cancer genome.

Using Complete Genomics' sequencing service, the Genentech team, led by Dr. Zemin Zhang, senior scientist, was able to detect significantly more somatic variations than have been discovered in other cancer studies (leukemia and breast cancer) conducted on a genome-wide basis. Genentech identified more than 50,000 high-confidence somatic single nucleotide variations (SNVs), which yielded an estimated genome-wide somatic mutation rate of 17.7 per Mb.

The Genentech researchers validated 392 somatic SNVs in coding regions, including one in the KRAS proto-oncogene. They also validated 43 large-scale structural variations in the tumor.

In addition, the researchers observed a distinct pattern of selection against mutations within expressed genes compared to non-expressed genes and in promoter regions up to 5 kb upstream of all protein-coding genes. This is the first time that such selection pressures within a tumor environment have been clearly identified.


Contact: Lisa Osborne
Complete Genomics

Related medicine news :

1. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
2. UCSF enters drug discovery agreement with Genentech
3. UCSF Enters Drug Discovery Agreement with Genentech
4. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
5. Now with Augmented Reality, Life Compass, by Fortune Compass, is the most complete Feng Shui App in Apple's iTunes store!
6. Impact Systems Successfully Completes EMC Documentum Migration for Global Pharmaceutical Client
7. LeveragePoint Releases Complete Online Value Management Solution
8. Vinomis Laboratories Completes Additional Funding Round
9. The Kramer Group Completes Strategic Name Change to Kramer Healthcare Technologies
10. CyberlinkASP Completes SAS 70 Type II Audit at Dallas Datacenter
11. Complete revascularization improves outcomes for CAD patients
Post Your Comments:
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology: